List of Excipients in Branded Drug FINGOLIMOD HYDROCHLORIDE

Generic Drugs Containing FINGOLIMOD HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Accord Healthcare Inc	fingolimod hydrochloride	16729-342	FERRIC OXIDE YELLOW
Accord Healthcare Inc	fingolimod hydrochloride	16729-342	FERROSOFERRIC OXIDE
Accord Healthcare Inc	fingolimod hydrochloride	16729-342	GELATIN
Accord Healthcare Inc	fingolimod hydrochloride	16729-342	MAGNESIUM STEARATE
Accord Healthcare Inc	fingolimod hydrochloride	16729-342	POTASSIUM HYDROXIDE
Accord Healthcare Inc	fingolimod hydrochloride	16729-342	SHELLAC

What are the Most Frequently-Used Excipients in FINGOLIMOD HYDROCHLORIDE?

# Of NDCs	Excipient
1	FERRIC OXIDE YELLOW
1	FERROSOFERRIC OXIDE
1	GELATIN
1	MAGNESIUM STEARATE
1	POTASSIUM HYDROXIDE
1	SHELLAC

Fingolimod Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Fingolimod hydrochloride is an established oral sphingosine-1-phosphate receptor modulator with a mature generic market. The commercial opportunity has shifted from basic capsule supply to differentiated excipient systems, pediatric delivery, lifecycle formulations, manufacturing efficiency, and regulatory support. The lowest-risk strategy is a conventional immediate-release capsule using compendial excipients. Higher-value opportunities involve oral liquids, sprinkleable multiparticulates, orally disintegrating tablets, taste masking, and excipient systems that improve content uniformity at the 0.5 mg dose.

What is the current pharmaceutical formulation of fingolimod hydrochloride?

Gilenya is supplied as a 0.5 mg hard gelatin capsule containing fingolimod hydrochloride. The FDA prescribing information identifies mannitol, magnesium stearate, gelatin, titanium dioxide, and yellow ferric oxide among the product ingredients and capsule components.[1]

Attribute	Gilenya reference product
Active ingredient	Fingolimod hydrochloride
Strength	0.5 mg fingolimod equivalent
Dosage form	Immediate-release hard gelatin capsule
Route	Oral
Primary therapeutic use	Relapsing forms of multiple sclerosis
Pediatric use	Patients aged 10 years and older, subject to labeling requirements
Core excipient functions	Bulking, lubrication, capsule formation, opacity, color
Regulatory reference	FDA-approved NDA 022527

The low drug load makes excipient selection important. At 0.5 mg, manufacturing performance depends on uniform blending, low segregation, and reliable dose recovery. The formulation does not require a complex modified-release matrix. Its technical challenge is dose uniformity rather than prolonged release.

Which excipients are most suitable for fingolimod hydrochloride capsules?

A generic immediate-release capsule can use a conventional, low-complexity excipient system. The main formulation objectives are blend uniformity, flow, capsule fill consistency, dissolution, chemical stability, and avoidance of excipient-driven bioequivalence risk.

Recommended excipient functions

Formulation function	Candidate excipients	Commercial rationale
Diluent	Mannitol, lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Controls fill weight and supports uniform distribution of the low-dose API
Glidant	Colloidal silicon dioxide	Improves powder flow and reduces fill-weight variation
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports capsule filling and ejection
Wetting or dispersion aid	Low-substituted hydroxypropyl cellulose, crospovidone, sodium lauryl sulfate at low levels	Can improve dispersion if dissolution is sensitive
Capsule shell	Gelatin or hypromellose	Supports conventional or vegetarian capsule positioning
Colorant and opacity agent	Titanium dioxide, iron oxides, permitted alternatives	Supports product identification and light protection
Taste-masking system	Polymer coating, lipid coating, ion-exchange resin, cyclodextrin complex	Relevant to liquid, ODT, and pediatric products

Mannitol is commercially attractive because it has good mouthfeel, low hygroscopicity relative to some polyols, and utility in both capsules and orally disintegrating products. Microcrystalline cellulose can improve compaction and flow but may produce a different dissolution profile from the reference product. Lactose is cost-effective, but its use requires assessment of moisture sensitivity, aldehyde-related compatibility, and supplier qualification.

Magnesium stearate is widely available and inexpensive. Excessive concentration or prolonged lubrication can reduce wetting and slow dissolution. Sodium stearyl fumarate offers a possible alternative where lower hydrophobicity or different processing behavior is required.

How should manufacturers solve the low-dose content-uniformity problem?

The primary technical risk is uniform distribution of a small quantity of fingolimod hydrochloride through a larger excipient mass. Direct blending can be viable, but it requires process controls that limit segregation during transfer, hopper discharge, and capsule filling.

Preferred manufacturing approaches

1. Geometric dilution
   The API is premixed with a small portion of diluent before incorporation into the final blend. This is simple and suitable for conventional generic development.

2. Ordered mixing
   API particles are associated with carrier particles or functionalized excipients to reduce segregation. Particle-size matching is critical.

3. Wet granulation
   Granulation can improve content uniformity and flow, but it adds water or solvent exposure, drying controls, and process complexity.

4. Dry granulation or roller compaction
   This approach avoids liquid exposure and can improve flow. It may alter dissolution and increase the risk of tablet or granule variability.

5. Spray-dried or co-processed excipients
   A co-processed mannitol-cellulose or similar platform can improve flow and compressibility for ODT or tablet products.

The highest-value excipient opportunity is a supplier-backed platform that provides a reproducible low-dose blending process. The commercial value lies less in the excipient alone than in the combination of material specification, particle engineering, mixing order, and validated manufacturing conditions.

What excipient strategies support pediatric fingolimod products?

Pediatric administration creates a larger formulation opportunity than the adult capsule market. Children may have difficulty swallowing hard capsules, and the FDA label includes pediatric patients aged 10 years and older.[1] A liquid, dispersible, or sprinkle product could improve administration, although the regulatory pathway and clinical bridging requirements must be assessed product by product.

Pediatric formulation options

Dosage form	Excipient strategy	Main benefit	Main development risk
Oral solution	Cosolvent, buffer, sweetener, preservative, flavor	Easy administration and flexible dosing	Chemical stability, taste, microbial control
Oral suspension	Suspending polymer, wetting agent, buffer, sweetener	Suitable for poorly soluble presentations	Dose uniformity after shaking and sedimentation
Powder for reconstitution	Mannitol or sucrose carrier, suspending agent, flavor	Improved shelf life before reconstitution	Reconstitution performance and packaging
Sprinkle capsule	Coated multiparticulates in a capsule	Can be opened and administered with soft food	Food interaction and dose recovery
ODT	Mannitol, crospovidone, low-moisture binder	Rapid disintegration and improved acceptability	Taste masking and mechanical strength
Oral granules	Functional carrier, flavor, polymer coating	Flexible administration	Content uniformity and handling

A pediatric liquid creates the strongest product differentiation but also the largest regulatory burden. Fingolimod has dose-dependent safety considerations, including first-dose monitoring requirements in the labeling.[1] A new dosage form must preserve accurate dosing and support the existing safety framework.

Taste masking

Taste masking is likely to be necessary for an oral liquid, ODT, or sprinkle formulation. Potential systems include polymer-coated drug particles, lipid-coated granules, ion-exchange resin complexes, and cyclodextrin-based complexes. The strategy must prevent premature release in the mouth without delaying gastrointestinal release.

A commercial developer should prioritize a taste-masking process that uses standard pharmaceutical equipment and scalable coating materials. A technically elegant complex with difficult recovery, low yield, or costly analytics may not compete with a conventional capsule.

What patents protect fingolimod hydrochloride formulations?

The foundational fingolimod patent estate is no longer the primary barrier to generic entry in major markets. Fingolimod products have faced generic competition, and FDA records identify approved ANDAs for fingolimod capsules.[2] The remaining IP assessment should focus on formulation, method-of-use, pediatric, manufacturing, and device claims rather than the original compound alone.

IP category	Relevance to fingolimod	Commercial risk
Original compound patents	Covered fingolimod and related compounds	Generally expired or commercially weak in the U.S.
Salt and polymorph claims	May address fingolimod hydrochloride or solid-state forms	Depends on claim scope and validity
Immediate-release capsule claims	Often difficult to sustain if they cover routine excipients	Low to moderate
Pediatric formulation claims	May cover liquid, sprinkle, or age-specific dosing	Moderate
Taste-masked particles	Can protect coated particles or release profiles	Moderate to high if narrowly engineered
Method-of-use claims	May cover relapsing MS populations or treatment regimens	Depends on listing and enforceability
Manufacturing claims	May protect particle engineering, blending, or granulation	Potentially meaningful for suppliers
Combination products	May cover fingolimod with another active agent	Usually limited to specific clinical programs

The Orange Book should be reviewed for the relevant reference product and current patent listings before an ANDA filing decision. An Orange Book patent listing does not establish validity, enforceability, or freedom to operate. A Paragraph IV certification may be required for listed patents that are not expired, while a Paragraph III certification may be appropriate for patents that remain valid but have later expiration dates.[3]

What is the Orange Book status of fingolimod?

FDA Orange Book records are the controlling source for current U.S. patent and exclusivity information. Gilenya is an NDA product, while generic fingolimod capsules are approved through the ANDA pathway.[2,3]

The practical U.S. market position is:

• The original branded product has lost U.S. market exclusivity.
• Generic fingolimod capsules are commercially available.
• The main formulation is a standard immediate-release capsule.
• Any remaining patent risk is product-specific and must be evaluated against current Orange Book listings, patent status, and proposed labeling.
• A differentiated dosage form may require a 505(b)(2) application rather than a conventional ANDA if it changes dosage form, route, formulation, or administration in a way that cannot be bridged through ordinary bioequivalence.

The six-month pediatric exclusivity associated with the reference product’s pediatric development period has also elapsed. FDA approval of Gilenya for pediatric patients aged 10 years and older occurred in 2018.[4]

When did fingolimod lose exclusivity and when can generics launch?

Fingolimod’s commercial exclusivity has already ended in the United States. The original compound and early product protection are no longer sufficient to prevent generic entry. Generic approvals began after patent litigation and settlement-related barriers were resolved or bypassed for particular applicants.

The relevant timeline is:

Period	Event
1990s	Fingolimod compound and related patent filings
2010	FDA approval of Gilenya
2018	FDA approval for pediatric patients aged 10 years and older
2019	Pediatric exclusivity period associated with the expanded indication ends
2022 onward	FDA generic fingolimod approvals and commercial generic entry
Current market	Mature generic capsule market with differentiation opportunities in dosage form and supply

Exact generic launch timing depends on applicant-specific litigation, settlement terms, approvals, manufacturing readiness, and commercial strategy. A new entrant should not assume that approval alone produces immediate market access.

Which companies are competing in fingolimod generics?

The competitive field includes Novartis as the reference-product sponsor and multiple generic manufacturers that have obtained or pursued fingolimod capsule approvals. FDA approval records and commercial databases should be used to identify the current ANDA holder and active suppliers because ownership, licensing, and marketing arrangements can change.[2]

The most credible competitive advantages are:

• Low-cost, high-throughput capsule manufacturing.
• Reliable API supply and dual sourcing.
• Strong content-uniformity process capability.
• Regional regulatory approvals.
• Pediatric or swallowability differentiation.
• Contract manufacturing capacity.
• Controlled distribution and hospital-channel access.
• A formulation patent that covers a meaningful clinical or manufacturing advantage.

A standard capsule has limited product differentiation. Margin improvement is more likely to come from procurement, yield, packaging, channel access, and regulatory execution than from a novel inactive ingredient.

What are the strongest commercial opportunities for fingolimod excipients?

1. Low-dose blending platforms

Excipient suppliers can sell a validated platform for uniform distribution of submilligram or low-milligram API loads. This can include co-processed carriers, particle-size specifications, electrostatic control, and blending protocols.

2. Pediatric liquids and dispersible products

A stable, palatable liquid or sprinkle product can address swallowing limitations and support lifecycle management. The opportunity is strongest where the product provides demonstrable administration benefits without changing the clinical dose.

3. Orally disintegrating tablets

An ODT could improve administration for patients who cannot swallow capsules. Mannitol-based systems, superdisintegrants, and taste-masked API particles are the most practical excipient components.

4. Capsule-shell substitution

Hypromellose capsules can support vegetarian positioning, lower moisture exposure, or specific supply-chain requirements. This is a limited opportunity unless the shell produces a clear stability or market-access advantage.

5. Manufacturing IP

Process patents covering drug layering, coated particles, co-processed excipients, or continuous manufacturing may be more defensible than patents covering routine capsule excipients. The strongest claims should connect the excipient system to a measurable result, such as content-uniformity improvement, dissolution control, stability, or dose recovery.

How does fingolimod compare with competing multiple sclerosis drugs?

Fingolimod competes with oral agents such as dimethyl fumarate and teriflunomide, as well as injectable and infusion therapies. The formulation opportunity differs by product type.

Product	Primary dosage form	Excipient opportunity
Fingolimod	Low-dose capsule	Content uniformity, pediatric delivery, taste masking
Dimethyl fumarate	Delayed-release capsule	Enteric polymers, acid protection, gastrointestinal tolerability
Teriflunomide	Tablet	Immediate-release tablet robustness and stability
Siponimod	Tablet	Low-dose uniformity and pharmacogenomic dosing support
Natalizumab	Infusion or injection	Biologic stability, surfactants, container closure

Fingolimod has a stronger fit for low-dose powder engineering and pediatric administration than for complex release-control technology. Its generic market also makes cost and execution more important than broad patent exclusivity.

What manufacturing and IP barriers remain?

The main manufacturing barriers are not unusual raw-material costs. They are process control and regulatory reproducibility.

Key barriers include:

• Demonstrating blend uniformity at the 0.5 mg strength.
• Controlling API particle-size distribution.
• Preventing segregation during transfer and filling.
• Matching dissolution to the reference product.
• Managing moisture and electrostatic behavior.
• Establishing two qualified excipient suppliers.
• Demonstrating stability in the selected capsule shell and packaging.
• Supporting global compendial and impurity specifications.
• Protecting any novel formulation without relying on routine excipient combinations.

For an excipient supplier, the most defensible commercial package combines a material, a process, analytical methods, regulatory documentation, and a customer-specific development agreement. A generic supplier selling only mannitol, magnesium stearate, or gelatin faces substantial price competition.

Key Takeaways

• Fingolimod hydrochloride is primarily an immediate-release, low-dose capsule product.
• The reference formulation uses conventional excipients, including mannitol and magnesium stearate.
• The central technical issue is content uniformity, not modified release.
• The U.S. market has moved beyond original-product exclusivity, with generic capsule approvals and competition established.
• Pediatric liquids, sprinkle products, ODTs, and taste-masked multiparticulates offer the clearest formulation opportunities.
• Excipient patents covering routine capsule compositions are likely to be weak unless linked to a measurable technical effect.
• Manufacturing platforms for low-dose blending may provide better commercial and IP value than commodity excipient sales.
• Orange Book listings, ANDA status, patent certifications, and applicant-specific litigation must be reviewed before a U.S. launch decision.
• A conventional capsule supports a 505(j) strategy; a substantially differentiated dosage form may require a 505(b)(2) pathway.
• Commercial success will depend on cost, supply reliability, dose uniformity, regulatory execution, and channel access.

FAQs

Can fingolimod hydrochloride be formulated as an oral liquid?

Yes. An oral liquid is technically feasible, but the formulation must address taste, chemical stability, dose uniformity, microbial control, packaging, and the regulatory effect of changing the dosage form.

Which excipient is best for a fingolimod ODT?

Mannitol is a strong starting diluent because it supports rapid disintegration and acceptable mouthfeel. Crospovidone or another superdisintegrant may improve disintegration, while taste-masked fingolimod particles may be necessary.

Is fingolimod hydrochloride a strong candidate for a generic capsule?

Yes. The established immediate-release capsule provides a relatively straightforward generic target, although the 0.5 mg dose creates meaningful content-uniformity and process-validation requirements.

Can a new fingolimod formulation receive patent protection?

Potentially. Patentability is more credible for a novel particle-engineering process, taste-masking architecture, pediatric delivery system, stability improvement, or manufacturing process than for a routine capsule containing standard excipients.

Are biosimilar risks relevant to fingolimod?

No. Fingolimod hydrochloride is a small-molecule drug. Competition proceeds through generic drug pathways rather than biosimilar approval pathways.

References

1. U.S. Food and Drug Administration. (2024). Gilenya (fingolimod) prescribing information.
2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, fingolimod products.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2018). FDA approves first drug to treat children and adolescents with multiple sclerosis.